Latest news for SoLVBL Solutions (OTC:SOLBF) Stock

SoLVBL Solutions Inc is a solution engineering company specializing in applications that address critical data integrity problems. Its products and services include a Supply-chain ecosystem, which enables a single entity to monitor, measure, and manage its inventory and supply management; and a Tracking system that provides a level of security by registering tracker profiles on the ledger using a 256-bit hash. It generates revenue through the sale of services for Blockchain software products.

SOLVBL SOLUTIONS INC by SOLVBL SOLUTIONS INC.

SoLVBL Solutions Inc

WIIM

FTNT

Fortinet shares are trading higher after TD Cowen upgraded the stock from Hold to Buy.

B of A Securities analyst Heather Balsky maintains Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) with a Buy and raises the price target from $255 to $286.

News

Price Target

Analyst Ratings

B of A Securities Maintains Buy on Equifax, Raises Price Target to $286

Commodities

Contracts

Markets

General

Sempra Infrastructure, A Subsidiary Of Sempra Announced Port Arthur LNG Phase 2 And Bechtel Energy Have Signed A Fixed-Price Engineering, Procurement And Construction Contract For The Port Arthur LNG Phase 2 Project Under Development In Port Arthur, Texas

BRKR

Bruker Posted Bond In Order To Suspend Injunction That Had Been Impacting Sales Of CosMx Spatial Molecular Imager Products By Its NanoString Business In Germany

Biotech

Health Care

MRNS

China National Medical Products Administration Has Approved Marinus Pharmaceuticals' Ganaxolone Oral Suspension For Epileptic Seizures In Patients Two Years Of Age And Older With CDKL5 Deficiency Disorder

Guidance

Hexcel Revised FY24 Outlook: Adj. EPS $2.02-$2.18 (From $2.10-$2.30) Vs. $2.21 Est., Revenue $1.90B-$1.98B (From $1.925B-$2.025B) Vs $1.955B Est.

B of A Securities analyst Kevin Fischbeck downgrades Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) from Buy to Neutral and lowers the price target from $646 to $530.

Downgrades

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

B of A Securities Downgrades Elevance Health to Neutral, Lowers Price Target to $530

SYRA

Siyata Mobile shares are trading higher after the company announced new orders for its SD7 handsets and related accessories valued at more than $4.5 million in aggregate for US wireless carriers.

INFY

Infosys Expects FY25 Revenue Growth of 3%-4% (Prior 1%-3%) in Constant Currency Vs $19.04B Est, Reiterated Operating Margin of 20%-22%

SYTA

Siyata Mobile Says It Expects To Deliver Record Sales In Q3 Ending September 30, 2024; Expects Q3 To Represent Best Sales Quarter In Company History

Dividends

VIRT

Virtu Financial Declared A Quarterly Cash Dividend Of $0.24 Per Share, Which Is Payable On September 15, 2024

AGEN

Agenus Announces End-of-Phase-2 Meeting Outcomes, Announces Topline Interim Phase 2 Data For BOT/BAL; Agreement Reached With FDA On Phase 3 Dose For BOT/BAL Combination

Siyata Mobile Bags New Orders For Its SD7 Handsets And Related Accessories Valued At More Than $4.5M In The Aggregate For US Wireless Carriers

IONS

Ionis Pharmaceuticals Has Completed Enrollment In The Pivotal Trial Of Zilganersen (ION373) For The Treatment Of Children And Adults With A Rare, Progressive Neurological Disorder Known As Alexander Disease. Topline Data Are Anticipated In 2H Of 2025

BMO Capital analyst Michael Zaremski upgrades Allstate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) from Market Perform to Outperform and raises the price target from $190 to $191.

Upgrades

BMO Capital Upgrades Allstate to Outperform, Raises Price Target to $191

Management

LICY

Li-Cycle Appoints Craig Cunningham To The Role Of CFO, Effective July 20, 2024

The monotherapy dose escalation phase of ELUCIDATE is designed to assess the safety, pharmacokinetics and pharmacodynamics of &#39;617 in advanced solid tumours.
Recruitment for the trial is progressing well with monotherapy dose escalation data on track to readout in the second half of 2024. In late 2024/early 2025, the study will transition to a combination dose escalation phase. The first tumour type to be explored in this portion of the study is expected to be HR+/HER2- breast cancer patients that have progressed on CDK4/6 inhibitors, assessing &lsquo;617 in combination with a selective estrogen receptor degrader (SERD).
&nbsp;Exscientia will pay GT Apeiron&nbsp;$10 million&nbsp;in upfront cash,&nbsp;$10 million&nbsp;in upfront equity, and take on all existing development costs, in addition to paying single digit royalties if Exscientia or a third party commercializes &#39;617. Following the transaction, Exscientia&#39;s cash runway is still expected to extend well into 2027.

EXAI

Exscientia Agrees To Acquire GT Apeiron's Share Of Its Oral CDK7 Inhibitor Program, Gaining Full Control Of GTAEXS617 And All Related Intellectual Property; To Pay GT Apeiron $10M Upfront Cash

Earnings

Marsh & McLennan Q2 2024 Adj EPS $2.41 Beats $2.40 Estimate, Sales $6.221B Miss $6.306B Estimate

Virtu Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRT#NASDAQ">VIRT</a>) reported quarterly earnings of $0.83 per share which beat the analyst consensus estimate of $0.60 by 38.33 percent. This is a 124.32 percent increase over earnings of $0.37 per share from the same period last year. The company reported quarterly sales of $385.08 million which beat the analyst consensus estimate of $331.57 million by 16.14 percent. This is a 38.18 percent increase over sales of $278.69 million the same period last year.

Earnings Beats

Virtu Finl Q2 Adj $0.83 Beats $0.60 Estimate, Adjusted Net Trading Income $385.08M Beat $331.57M Estimate

Hexcel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HXL#NYSE">HXL</a>) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0.56 by 7.14 percent. The company reported quarterly sales of $500.400 which missed the analyst consensus estimate of $483.362 million by 100.00 percent. This is a 100.00 percent decrease over sales of $454.300 million the same period last year.

Earnings Misses

Hexcel Q2 2024 Adj EPS $0.60 Beats $0.56 Estimate, Sales $500.400 Miss $483.362M Estimate

SoLVBL Solutions

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

SoLVBL Solutions

News

Latest news for SoLVBL Solutions (OTC:SOLBF) Stock